The World Health Organization (WHO) has granted prequalification to the molecular diagnostic test for tuberculosis (TB) ...
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, has announced i...
US-based GE HealthCare has announced its work with Peter MacCallum Cancer Centre in Australia to further develop and exp...
Newbase, a leader in metaverse-based medical education platforms, has announced the launch of its new product, 'Medicrew...
Neurophet, an artificial intelligence (AI) solution company for brain disease, has announced that its brain MRI analysis...
King Faisal Specialist Hospital & Research Centre (KFSHRC) has unveiled its state-of-the-art Virtual Pathology Servi...
South Korea-based Lunit, a leading provider of artificial intelligence (AI)-powered solutions for cancer diagnostics and...
SpaceGut, part of SOL Partnership Sdn Bhd, has introduced Malaysia's first artificial intelligence (AI)-p...
• The largest edition yet, nearly double the size of the 2023 edition.• Hall A1 fully booked six months in adv...
Japan-based Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately JPY 578 mi...
A recent prospective cross-sectional study in Thailand demonstrates that multi-target stool DNA testing is highly sensit...
The Ministry of Health and Prevention (MoHAP), United Arab Emirates (UAE) has signed a strategic agreement with AstraZen...
US-based Inocras Inc. and Summit Pharmaceuticals International Corporation have signed a Memorandum of understanding (Mo...
In an insightful interview with BioSpectrum Asia, Shaun Rothwell, CEO of EVŌQ Nano, reveals the transformative potentia...
Volpara Health, a South Korea-based Lunit company and a global leader in software for the early detection of cancer, has...
South Korea-based startup Neurophet, an artificial intelligence (AI) solution company for brain disease, has secured a s...
4baseCare, an Illumina Accelerator Company, that offers cutting-edge precision oncology solutions using advanced genomic...
Oncomine Dx Target Test to Identify Patients Eligible for Servier’s VORANIGO® (vorasidenib) tablet, the only F...
